Wellington Management Group LLP Allakos Inc. Transaction History

Wellington Management Group LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$8.55 - $111.89 $32.6 Million - $427 Million	-3,818,044 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$76.53 - $110.43 $9.23 Million - $13.3 Million	120,668 Added 3.26%	3,818,044 $404 Million
Q2 2021 Aug 16, 2021	BUY	$85.37 - $114.1 $20.6 Million - $27.5 Million	241,172 Added 6.98%	3,697,376 $316 Million
Q1 2021 May 17, 2021	BUY	$109.73 - $153.66 $161 Million - $225 Million	1,466,218 Added 73.68%	3,456,204 $397 Million
Q4 2020 Feb 12, 2021	BUY	$79.58 - $152.45 $87.6 Million - $168 Million	1,100,267 Added 123.66%	1,989,986 $279 Million
Q3 2020 Nov 16, 2020	BUY	$66.43 - $90.99 $9.66 Million - $13.2 Million	145,485 Added 19.55%	889,719 $72.5 Million
Q2 2020 Aug 14, 2020	BUY	$44.04 - $80.69 $7.33 Million - $13.4 Million	166,417 Added 28.8%	744,234 $53.5 Million
Q1 2020 May 14, 2020	BUY	$44.49 - $93.39 $14.3 Million - $29.9 Million	320,435 Added 124.5%	577,817 $25.7 Million
Q4 2019 Feb 11, 2020	BUY	$66.49 - $137.73 $17.1 Million - $35.4 Million	257,382 New	257,382 $24.5 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $82.2M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.